Stock 002688 JINHE BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jinhe Biotechnology CO., LTD.

Equities

002688

CNE100001HK7

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.82 CNY +0.79% Intraday chart for Jinhe Biotechnology CO., LTD. +6.70% -20.58%
Apr. 03 Tranche Update on Jinhe Biotechnology CO., LTD.'s Equity Buyback Plan announced on February 6, 2024. CI
Feb. 05 Jinhe Biotechnology CO., LTD. announces an Equity Buyback for CNY 100 million worth of its shares. CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 3,977 2,833 3,996 3,488 4,784 3,874
Enterprise Value (EV) 1 4,528 3,541 4,830 4,506 5,274 4,985
P/E ratio 36.8 x 17.2 x 21.7 x 30.5 x 43.8 x 53.1 x
Yield 0.48% 5.61% 3.97% 1.82% - 1.95%
Capitalization / Revenue 2.73 x 1.74 x 2.24 x 1.92 x 2.3 x 1.83 x
EV / Revenue 3.11 x 2.17 x 2.71 x 2.48 x 2.54 x 2.35 x
EV / EBITDA 16.1 x 11.7 x 14.2 x 13.6 x 15.8 x 17.7 x
EV / FCF -34.9 x -29 x 176 x -58.8 x -17.9 x -27.3 x
FCF Yield -2.86% -3.45% 0.57% -1.7% -5.58% -3.66%
Price to Book 2.61 x 1.69 x 2.38 x 2.16 x 1.96 x 1.74 x
Nbr of stocks (in thousands) 635,290 635,290 635,290 635,290 780,422 753,752
Reference price 2 6.260 4.460 6.290 5.490 6.130 5.140
Announcement Date 3/14/18 3/28/19 4/19/20 3/30/21 4/21/22 4/21/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 1,458 1,629 1,782 1,815 2,078 2,123
EBITDA 1 281.6 301.6 340.1 330.7 333.8 282.1
EBIT 1 209.3 215.4 240.8 210.9 203 133.1
Operating Margin 14.35% 13.22% 13.51% 11.62% 9.77% 6.27%
Earnings before Tax (EBT) 1 147.4 194.5 220.2 140.9 142.9 118.8
Net income 1 108.4 163.6 184.9 117.3 93.99 75.54
Net margin 7.44% 10.05% 10.38% 6.47% 4.52% 3.56%
EPS 2 0.1700 0.2600 0.2900 0.1800 0.1400 0.0968
Free Cash Flow 1 -129.6 -122 27.49 -76.67 -294.4 -182.3
FCF margin -8.89% -7.49% 1.54% -4.22% -14.17% -8.59%
FCF Conversion (EBITDA) - - 8.08% - - -
FCF Conversion (Net income) - - 14.87% - - -
Dividend per Share 2 0.0300 0.2500 0.2500 0.1000 - 0.1000
Announcement Date 3/14/18 3/28/19 4/19/20 3/30/21 4/21/22 4/21/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 551 708 834 1,019 490 1,110
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.956 x 2.346 x 2.453 x 3.08 x 1.469 x 3.937 x
Free Cash Flow 1 -130 -122 27.5 -76.7 -294 -182
ROE (net income / shareholders' equity) 6.83% 9.62% 10.6% 7.83% 5.49% 4.61%
ROA (Net income/ Total Assets) 4.65% 4.28% 4.51% 3.92% 3.41% 1.94%
Assets 1 2,330 3,826 4,103 2,991 2,756 3,891
Book Value Per Share 2 2.400 2.640 2.640 2.540 3.120 2.950
Cash Flow per Share 2 0.5400 0.7700 0.5700 0.5000 0.6600 0.6500
Capex 1 197 170 179 204 384 402
Capex / Sales 13.48% 10.45% 10.03% 11.24% 18.47% 18.95%
Announcement Date 3/14/18 3/28/19 4/19/20 3/30/21 4/21/22 4/21/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Veterinary Drugs

1st Jan change Capi.
JINHE BIOTECHNOLOGY CO., LTD. Stock Jinhe Biotechnology CO., LTD.
-20.58% 397M
ZOETIS INC. Stock Zoetis Inc.
-19.73% 72.39B
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
-11.01% 6.54B
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+15.88% 3.43B
VIMIAN GROUP AB Stock Vimian Group AB
-0.68% 1.4B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-17.27% 1.34B
VETOQUINOL SA Stock Vetoquinol SA
-2.73% 1.26B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-28.16% 1.2B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-14.67% 1.12B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-5.37% 990M
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. 002688 Stock
  4. Financials Jinhe Biotechnology CO., LTD.